DFDA

Hypoglossal Nerve Stimulation (HGNS)

Treatment for Sleep Apnea

Typical Dosage: Device programmed settings

Effectiveness
80%
Safety Score
65%
Clinical Trials
14
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Device programmed settings
Time to Effect
2-3 months
Treatment Duration
Lifetime (with battery replacements)
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$300
Side Effect Mgmt:$100
Total Annual:$4,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$75,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$6,923
Cost per Remission
$10,000
Hypoglossal Nerve Stimulation (HGNS) Outcomes

for Sleep Apnea

Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+65%
Remission Rate
+45%
Common Side Effects
Tongue weakness/discomfort
+15%
Lead infection/migration
+3%
Speech disturbance
+5%
Battery replacement surgery
+100%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
8 active trials recruiting for Hypoglossal Nerve Stimulation (HGNS) in Sleep Apnea

Metabolic Endpoints for Obstructive Sleep Apnea Following Twelfth Cranial Nerve Stimulation

NCT06317701RECRUITING
View Study
30 participants
OBSERVATIONAL
Chicago, United States
Started: Apr 4, 2024

Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy

NCT06720545RECRUITINGNA
View Study
60 participants
INTERVENTIONAL
New York, United States
Started: Jan 5, 2025

Hypoglossal Nerve Stimulation for the Treatment of Adult Obstructive Sleep Apnea

NCT07049744RECRUITINGNA
View Study
30 participants
INTERVENTIONAL
Canberra, Australia +4 more
Started: Jun 24, 2025

Obstructive Sleep Apnea Non-PAP Outcomes and Viable Alternatives

NCT07074288RECRUITINGNA
View Study
60 participants
INTERVENTIONAL
St Louis, United States
Started: Jun 30, 2025

Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation

NCT07220525RECRUITINGNA
View Study
100 participants
INTERVENTIONAL
San Francisco, United States
Started: Oct 31, 2025

Reducing Obstructive Sleep Apnea After Hypoglossal Nerve Stimulation Through Mandibular Advancement

NCT07132307RECRUITINGNA
View Study
30 participants
INTERVENTIONAL
St Louis, United States
Started: Jul 29, 2025

An Extension Study to Assess the Long-term Safety of the Genio® System

NCT05939141NOT YET RECRUITING
View Study
39 participants
OBSERVATIONAL
Sydney, Australia +6 more
Started: Nov 1, 2025

Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.

NCT05592002ACTIVE NOT RECRUITINGNA
View Study
124 participants
INTERVENTIONAL
Colorado Springs, United States +15 more
Started: Dec 28, 2022
Completed Clinical Trials
3 completed trials for Hypoglossal Nerve Stimulation (HGNS) in Sleep Apnea

Hypoglossal Nerve Stimulation on Cardiovascular Outcomes

NCT03359096COMPLETEDNA
View Study
63 participants
INTERVENTIONAL
Philadelphia, United States
Started: Dec 13, 2017

US Clinical Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea

NCT01211444COMPLETEDPHASE2, PHASE3
View Study
20 participants
INTERVENTIONAL
San Francisco, United States +3 more
Started: Jul 1, 2010

Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep Apnea

NCT01186926COMPLETEDPHASE2, PHASE3
View Study
40 participants
INTERVENTIONAL
Started: Mar 1, 2009